Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07589608 · ClinicalTrials.gov registry record · Phase 2
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
A Phase 2 study, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 400
- Enrollment target
NCT07589608 is a Phase 2 study that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 400 participants.
The verdict
NCT07589608, a Phase 2 study, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 400 participants
- Enrollment target
Study Summary
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with placebo in participants with obesity or overweight and without type 2 diabetes. Participation will last about 64 weeks.
Interventions
- DRUG Placebo
- DRUG Eloralintide
- DRUG Macupatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2026-05-15 |
| Est. Completion | 2028-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07589608
The ClinicalTrials.gov registry entry for NCT07589608 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT07589608 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07589608 about?
NCT07589608 is a clinical study titled "A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight". The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with placebo in participants with obesity or overweight and without type 2 diabetes. Participation will l...
What is the current status of trial NCT07589608?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 400 participants. The study started on 2026-05-15. Estimated completion is 2028-02.
What interventions are being tested in trial NCT07589608?
The interventions under investigation include: Placebo (DRUG), Eloralintide (DRUG), Macupatide (DRUG).
Who is sponsoring clinical trial NCT07589608?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.